Clinical trial · Observational
Correlation Between Driver Gene Abnormalities and Clinicopathological Characteristics and Disease Prognosis in Lymphoma
NCT04263935CI-TRIAL-00088821recruitingClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
Correlation Between Driver Gene Abnormalities and Clinicopathological Characteristics and Disease Prognosis in Lymphoma
Conditions
Conditions (2)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Gene Abnormality | — | UNRESOLVED | — |
| Lymphoma | Lymphoma | ONTOLOGY_EXACT | 0.90 |
Interventions
Interventions (0)
Data not yet available
No intervention recorded.
Design
Arms and outcomes
Arms (0)
[]Primary outcomes (1)
- measure
- Incidence of driver gene abnormalities
- timeFrame
- from the day of the first patient was included to the date of the end of this trial, assessed up to 36 months
- description
- the incidence of driver gene abnormalities by fixed gene testing technology
Secondary outcomes (3)
- measure
- objective response rate
- timeFrame
- from the date of the first patient was included to the date of the end of this trial, assessed up to 36 months
- description
- the total proportion of patients with complete response (CR) and partial response (PR)
- measure
- 5-year overall survival
- timeFrame
- from the date of the first patient was included to the date of the end of this trial, assessed up to 5 years
- description
Eligibility
Eligibility (as posted)
- Sex
- All
Show eligibility criteria text
Inclusion Criteria: 1. Diagnosed as lymphoma (according to WHO 2017 classification criteria) 2. Life expectancy no less than 3 months 3. Agreeing to sign the written informed consents Exclusion Criteria: 1. Other malignant tumor history or active malignant tumor need be treated 2. Researchers determine unsuited to participate in this trial
References
Publications (0)
Data not yet available
No reference posted for this study.